Lumida
/WGS
⌘K
GeneDx Holdings Corp

GeneDx Holdings Corp

WGS
$63.48USD↑+2.90%+1.79 today

MARKET CAP

1.9B

P/E (TTM)

74.7x

FWD P/E

54.1x

DAY RANGE

$59 – $64

52W RANGE

$32
$171

AI Summary

Stalk
TrimMedium

WGS is in a Stage 3 distribution phase with a bearish medium-term bias reinforced by a double top and failed breakout above prior highs. Price is currently tracking above the 9/21 EMA and 50 DMA cluster with no clear rejection, so immediate shorting is premature. Look to trim exposure into rebounds toward the EMA and 50 DMA zone. The long-term uptrend remains intact but is overshadowed by near-term distribution risks.

  • ↑Test volume surged 34% YoY to 27,488 in Q1.
  • ↑Q1 revenue $102.3M (+17% YoY) with avg reimbursement ~$3,700/test.
  • ↓$31.2M impairment led to multiple securities class-action lawsuits.
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

GeneDx Holdings Corp. (NASDAQ: GNDX) is a leader in genomic testing focused on advanced genetic diagnostics for rare diseases. The firm utilizes its substantial proprietary database, GeneDx Infinity, to provide rapid and accurate diagnostic services, primarily through whole exome and whole genome sequencing. Positioned in the healthcare sector, GeneDx is capitalizing on the growing demand for personalized medicine and proactive healthcare solutions, particularly among pediatric populations. The company operates on the frontier of genomic diagnostics, striving to become a pivotal player in transforming healthcare through innovative genetic testing.

Bull says

  • ↑Test volume surged 34% YoY to 27,488 in Q1.
  • ↑Q1 revenue $102.3M (+17% YoY) with avg reimbursement ~$3,700/test.
  • ↑2026 revenue guidance set at $475–490M.
  • ↑NICU testing penetration under 5% implies a $1B market.
  • ↑Strong institutional backing and proprietary Infinity database build moat.

Bear says

  • ↓$31.2M impairment led to multiple securities class-action lawsuits.
  • ↓Q1 revenue missed estimates by $12M, stock plunged 40%.
  • ↓2026 guidance cut 12% to $475–490M reflects headwinds.
  • ↓Operating expenses rising with expanded sales force, squeezing margins.
  • ↓High volatility, weak profitability, negative earnings yield heighten risk.

Investment themes with WGS

Health Care Providers↓ -0.61%

UNH · CVS · HCA

Earnings Call · Q1 2025 · Mgmt. Guidance

Updated 06-04-2026neutral

Transcript signals

Bull points

  • Our team's work surpassed our expectations and delivered a strong first quarter with revenues exceeding $87 million and our third consecutive quarter of profitability.
  • We're raising guidance for the year to $360 million to $375 million, successfully building on last year's momentum and strengthening our industry-leading position centered on diagnosing any genetic disease as early as possible with whole exome and genome sequencing.
  • Our ultra-rapid genome sequencing product, which delivers results in as soon as 48 hours, is being well-received in terms of its two-day turnaround time and price point.

Bear points

  • As genomic testing adoption grows worldwide, Fabric Genomics' cloud-native platform will expand GeneDx's ability to serve a global market with tailored commercial models aligned with foreign regulations.
  • On the latter, I'd expect hereditary cancer to be zero or near zero in the second half of the year. So only some residual effects here for the remainder of the second quarter.
  • the scarcity of expert geneticists and pediatric specialists who order these tests today, i.e., a pediatric neurologist or a geneticist, there's just long wait times to get back into the office.
Read full transcript analysis ›